Versions
- 18-07-2023 (2)
- 26-06-2023 (1)
Keywords
Theranostics
Nuclear medicine
How to Cite
Abstract
Teranostyka ma na celu indywidualizację postępowania diagnostycznego i terapeutycznego. Obecnie Theranostics jest najczęściej stosowany w diagnostyce i terapii pacjentów z guzami neuroendokrynnymi oraz rakiem prostaty. Głównym celem Theranostics jest wykorzystanie radiofarmaceutyków umożliwiających obrazowanie i leczenie choroby. Lutet-177 i aktyn-225 to obecnie najczęściej stosowane radioznaczniki w teranostyce.
References
Włodek, M. 2020. Prostate cancer – what is the best therapy we should treat our patients with. Letters in Oncology Science. 17, 3 (Sep. 2020), 15–22.
Pikala M, Burzyńska M, Maniecka-Bryła I. Epidemiology of Mortality Due to Prostate Cancer in Poland, 2000-2015. Int J Environ Res Public Health. 2019 Aug 12;16(16):2881. doi: 10.3390/ijerph16162881. PMID: 31409038; PMCID: PMC6721133.
Litwin MS, Tan HJ. The Diagnosis and Treatment of Prostate Cancer: A Review. JAMA. 2017 Jun 27;317(24):2532-2542. doi: 10.1001/jama.2017.7248. PMID: 28655021.
Schlemmer HP, Krause BJ, Schütz V, Bonekamp D, Schwarzenböck SM, Hohenfellner M. Imaging of Prostate Cancer. Dtsch Arztebl Int. 2021 Oct 22;118(42):713-719. doi: 10.3238/arztebl.m2021.0309. PMID: 34427180; PMCID: PMC8767150.
Bjöersdorff M, Puterman C, Oddstig J, Amidi J, Zackrisson S, Kjölhede H, Bjartell A, Wollmer P, Trägårdh E. Detection of lymph node metastases in patients with prostate cancer: Comparing conventional and digital [18F]-fluorocholine PET-CT using histopathology as a reference. Clin Physiol Funct Imaging. 2022 Nov;42(6):381-388. doi: 10.1111/cpf.12770. Epub 2022 Aug 8. PMID: 35866190.
Choudhury PS, Gupta M. Differentiated thyroid cancer theranostics: radioiodine and beyond. Br J Radiol. 2018 Nov;91(1091):20180136. doi: 10.1259/bjr.20180136. Epub 2018 Oct 11. PMID: 30260232; PMCID: PMC6475953.
Kaewput C, Vinjamuri S. Update of PSMA Theranostics in Prostate Cancer: Current Applications and Future Trends. J Clin Med. 2022 May 12;11(10):2738. doi: PMID: 35628867; PMCID: PMC9144463.
Mokoala K, Lawal I, Lengana T, Kgatle M, Giesel FL, Vorster M, Sathekge M. PSMA Theranostics: Science and Practice. Cancers (Basel). 2021 Aug 2;13(15):3904. doi: 10.3390/cancers13153904. PMID: 34359805; PMCID: PMC8345360.
] Maurer T, Eiber M, Schwaiger M, Gschwend JE. Current use of PSMA-PET in prostate cancer management. Nat Rev Urol. 2016 Apr;13(4):226-35. doi: 10.1038/nrurol.2016.26. Epub 2016 Feb 23. PMID: 26902337.
Mayor N, Sathianathen NJ, Buteau J, Koschel S, Antón Juanilla M, Kapoor J, Azad A, Hofman MS, Murphy DG. Prostate-specific membrane antigen theranostics in advanced prostate cancer: an evolving option. BJU Int. 2020 Nov;126(5):525-535. doi: 10.1111/bju.15143. Epub 2020 Aug 12. PMID: 32559353
Uprimny C. 68Ga-PSMA-11 PET/CT: the rising star of nuclear medicine in prostate cancer imaging? Wien Med Wochenschr. 2019 Feb;169(1-2):3-11. doi: 10.1007/s10354-017-0569-z. Epub 2017 Jun 2. PMID: 28577076.
Esen T, Kılıç M, Seymen H, Acar Ö, Demirkol MO. Can Ga-68 PSMA PET/CT replace conventional imaging modalities for primary lymph node and bone staging of prostate cancer? Eur Urol Focus. 2020 Mar 15;6(2):218-220. doi: 10.1016/j.euf.2019.05.005. Epub 2019 May 18. PMID: 31113757.
Keam SJ. Lutetium Lu 177 Vipivotide Tetraxetan: First Approval. Mol Diagn Ther. 2022 Jul;26(4):467-475. doi: 10.1007/s40291-022-00594-2. Epub 2022 May 13. PMID: 35553387; PMCID: PMC9099330.
Abuqbeitah M, Demir M, Uslu-Beşli L, Yeyin N, Sönmezoğlu K. Blood clearance and occupational exposure for 177Lu-DOTATATE compared to 177Lu-PSMA radionuclide therapy. Radiat Environ Biophys. 2018 Mar;57(1):55-61. doi: 10.1007/s00411-017-0721-6. Epub 2017 Nov 17. PMID: 29149420.
Kabasakal L, Toklu T, Yeyin N, Demirci E, Abuqbeitah M, Ocak M, Aygün A, Karayel E, Pehlivanoğlu H, Alan Selçuk N. Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry. Mol Imaging Radionucl Ther. 2017 Jun 1;26(2):62-68. doi: 10.4274/mirt.08760. PMID: 28613198; PMCID: PMC5472088.
Chandran E, Figg WD, Madan R. Lutetium-177-PSMA-617: A Vision of the Future. Cancer Biol Ther. 2022 Dec 31;23(1):186-190. doi: 10.1080/15384047.2022.2037985. PMID: 35220877; PMCID: PMC8890398.
Hooijman EL, Chalashkan Y, Ling SW, Kahyargil FF, Segbers M, Bruchertseifer F, Morgenstern A, Seimbille Y, Koolen SLW, Brabander T, de Blois E. Development of [225Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC. Pharmaceutics. 2021 May 13;13(5):715. doi: 10.3390/pharmaceutics13050715. PMID: 34068206; PMCID: PMC8153125.
Rathke H, Kratochwil C, Hohenberger R, Giesel FL, Bruchertseifer F, Flechsig P, Morgenstern A, Hein M, Plinkert P, Haberkorn U, Bulut OC. Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing 225Ac-PSMA-617 RLT. Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):139-147. doi: 10.1007/s00259-018-4135-8. Epub 2018 Aug 27. PMID: 30151743.
Poeppel TD, Handkiewicz-Junak D, Andreeff M, Becherer A, Bockisch A, Fricke E, Geworski L, Heinzel A, Krause BJ, Krause T, Mitterhauser M, Sonnenschein W, Bodei L, Delgado-Bolton RC, Gabriel M. EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2018 May;45(5):824-845. doi: 10.1007/s00259-017-3900-4. Epub 2017 Dec 12. PMID: 29234845.
Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland ØS, Sartor O; ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013 Jul 18;369(3):213-23. doi: 10.1056/NEJMoa1213755. PMID: 23863050.
Nilsson S. Radium-223 Therapy of Bone Metastases in Prostate Cancer. Semin Nucl Med. 2016 Nov;46(6):544-556. doi: 10.1053/j.semnuclmed.2016.07.007. Epub 2016 Sep 15. PMID: 27825434.
Dandapani SV, Wong J, Twardowski P. Review of Radium-223 and Metastatic Castration-Sensitive Prostate Cancer. Cancer Biother Radiopharm. 2020 Sep;35(7):490-496. doi: 10.1089/cbr.2019.3493. Epub 2020 Aug 6. PMID: 32762539.
Miranda J, Viñal D, Pinto Á. Radium 223 for the treatment of metastatic castration-resistant prostate cancer. Arch Esp Urol. 2019 Jun;72(5):500-507. English, Spanish. PMID: 31223127.
van der Doelen MJ, Mehra N, Hermsen R, Janssen MJR, Gerritsen WR, van Oort IM. Patient Selection for Radium-223 Therapy in Patients With Bone Metastatic Castration-Resistant Prostate Cancer: New Recommendations and Future Perspectives. Clin Genitourin Cancer. 2019 Apr;17(2):79-87. doi: 10.1016/j.clgc.2018.11.008. Epub 2018 Nov 22. PMID: 30558834.
Schatten H. Brief Overview of Prostate Cancer Statistics, Grading, Diagnosis and Treatment Strategies. Adv Exp Med Biol. 2018;1095:1-14. doi: 10.1007/978-3-319-95693-0_1. PMID: 30229546.
Eissa A, Elsherbiny A, Coelho RF, Rassweiler J, Davis JW, Porpiglia F, Patel VR, Prandini N, Micali S, Sighinolfi MC, Puliatti S, Rocco B, Bianchi G. The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature. Minerva Urol Nefrol. 2018 Oct;70(5):462-478. doi: 10.23736/S0393-2249.18.03081-3. Epub 2018 Apr 17. PMID: 29664244.
Sanli Y, Simsek DH, Sanli O, Subramaniam RM, Kendi AT. 177Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer. Biomedicines. 2021 Apr 15;9(4):430. doi: 10.3390/biomedicines9040430. PMID: 33921146; PMCID: PMC8071500.
Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, Kopka K, Apostolidis C, Haberkorn U, Morgenstern A. 225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2016 Dec;57(12):1941-1944. doi: 10.2967/jnumed.116.178673. Epub 2016 Jul 7. PMID: 27390158.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyright (c) 2023 Letters in Oncology Science